Drug repositioning: a brief overview.


Journal

The Journal of pharmacy and pharmacology
ISSN: 2042-7158
Titre abrégé: J Pharm Pharmacol
Pays: England
ID NLM: 0376363

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 14 02 2020
revised: 17 03 2020
accepted: 21 03 2020
pubmed: 18 4 2020
medline: 29 5 2021
entrez: 18 4 2020
Statut: ppublish

Résumé

Drug repositioning, that is, the use of a drug in an indication other than the one for which it was initially marketed, is a growing trend. Its origins lie mainly in the attrition experienced in recent years in the field of new drug discovery. Despite some regulatory and economic challenges, drug repositioning offers many advantages, and a number of recent successes have confirmed both its public health benefits and its commercial value. The first examples of successful drug repositioning mainly came about through serendipity like acetylsalicylic acid, thalidomide, sildenafil or dimethylfumarate. The history of great-repositioned drugs has given some solutions to various pathologies. Serendipity is not yet useful to find repositioning drugs. Drug repositioning is of growing interest. Nowadays, a more rational approach to the identification of drug candidates for repositioning is possible, especially using data mining.

Identifiants

pubmed: 32301512
doi: 10.1111/jphp.13273
pmc: PMC7262062
doi:

Types de publication

Historical Article Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1145-1151

Informations de copyright

© 2020 Royal Pharmaceutical Society.

Références

Nat Rev Drug Discov. 2004 Aug;3(8):673-83
pubmed: 15286734
Lancet. 2011 Jan 1;377(9759):31-41
pubmed: 21144578
Alzheimers Dement (N Y). 2017 May 24;3(3):367-384
pubmed: 29067343
Nature. 2016 Jun 14;534(7607):314-6
pubmed: 27306171
PLoS One. 2016 Dec 22;11(12):e0168812
pubmed: 28005991
Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11301-6
pubmed: 9736731
Nat Rev Drug Discov. 2019 Jan;18(1):41-58
pubmed: 30310233
Nat Rev Drug Discov. 2012 Mar 01;11(3):191-200
pubmed: 22378269
Sci Data. 2017 Mar 14;4:170029
pubmed: 28291243
Nat Biotechnol. 2015 Apr;33(4):342-5
pubmed: 25850054
Int J Antimicrob Agents. 2020 Apr;55(4):105932
pubmed: 32145363
Nat New Biol. 1971 Jun 23;231(25):232-5
pubmed: 5284360
Brief Bioinform. 2011 Jul;12(4):341-5
pubmed: 21357612
J Chem Inf Model. 2015 Feb 23;55(2):446-59
pubmed: 25602292
Drug Discov Today. 2017 May;22(5):805-813
pubmed: 28363518
Drug Discov Today. 2006 Feb;11(3-4):160-4
pubmed: 16533714
Drug Discov Today. 2015 Aug;20(8):1027-34
pubmed: 25975957
Front Pharmacol. 2017 May 23;8:298
pubmed: 28588497
N Engl J Med. 1999 Nov 18;341(21):1606-9
pubmed: 10564693

Auteurs

Jean-Pierre Jourdan (JP)

UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Normandie Univ., Caen, France.
Pharmacy Department, CHRU de Caen, Caen, France.

Ronan Bureau (R)

UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Normandie Univ., Caen, France.

Christophe Rochais (C)

UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Normandie Univ., Caen, France.

Patrick Dallemagne (P)

UNICAEN, Centre d'Etudes et de Recherche sur le Médicament de Normandie (CERMN), Normandie Univ., Caen, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH